CN109329202A - It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method - Google Patents
It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method Download PDFInfo
- Publication number
- CN109329202A CN109329202A CN201811139284.7A CN201811139284A CN109329202A CN 109329202 A CN109329202 A CN 109329202A CN 201811139284 A CN201811139284 A CN 201811139284A CN 109329202 A CN109329202 A CN 109329202A
- Authority
- CN
- China
- Prior art keywords
- stomach
- 3gal
- filling
- kaempferol
- synthetic method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Abstract
Effectively inhibit NeuGc ALPHA2-3Gal synthetic method the invention discloses a kind of, this method are as follows: treat and kill the perfusion of meat products living animal, pass through peroral routes of administration stomach-filling mode, administration is Kaempferol, 0.5% carboxymethylcellulose sodium solution is used to carry out being configured to 1mL solution, each stomach-filling amount is 1mL/d, stomach-filling 29-31d.The present invention inhibits the substrate of CMP-Neu5Ac hydroxylase using natural Flavonoid substances, and then influences the activity of CMP-Neu5Ac hydroxylase, reaches the synthesis for reducing Neu5Gc.The intervention of NeuGc ALPHA2-3Gal biochemistry synthesis is carried out in living body before killing, at low cost, effect is more obvious.
Description
Technical field
Effectively inhibit NeuGc ALPHA2-3Gal synthetic method the present invention relates to a kind of, belongs to and inhibit N- hydroxyl acetyl nerve
Propylhomoserin synthesis technical field.
Background technique
Existing inhibition NeuGc ALPHA2-3Gal synthetic technology includes: mainly including physical method (boiling, microwave, frying)
And addition enzyme preparation reduces the content of the NeuGc ALPHA2-3Gal in meat products, but there are the problem of have: (1) pass through
Physical method reduces Neu5Gc content there are many shortcomings, such as boiling, microwave, frying are only capable of making the Neu5Gc water of free state
Solution comes out, and most reference state Neu5Gc is still trapped in meat products；(2) by enzyme preparation method reduce Neu5Gc, be only capable of from
It is handled after government official, and since meat sample matrix is complicated, hydrolysis result is unsatisfactory.
Summary of the invention
The technical problem to be solved by the present invention is a kind of effectively inhibition NeuGc ALPHA2-3Gal synthetic method is provided,
To solve above-mentioned problems of the prior art.
The technical scheme adopted by the invention is as follows: it is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method, this method
Are as follows: it treats government official's meat products living animal and fills Kaempferol, by peroral routes of administration stomach-filling mode, Kaempferol is used to 0.5% carboxylic
Methylcellulose sodium solution carries out being configured to 1mL solution, and each stomach-filling amount is 1mL/d, stomach-filling 29-31d.
Kaempferol amount is 190-210mg/ (kg.d).
What the synthesis of Neu5Gc played a crucial role is CMP-Neu5Ac hydroxylase.
Beneficial effects of the present invention: compared with prior art, the present invention is inhibited using natural Flavonoid substances Kaempferol
The substrate of CMP-Neu5Ac hydroxylase, and then the activity of CMP-Neu5Ac hydroxylase is influenced, reach the synthesis for reducing Neu5Gc.From
The intervention of NeuGc ALPHA2-3Gal biochemistry synthesis is carried out before killing in living body, at low cost, effect is more obvious.
Detailed description of the invention
Fig. 1 is to feed 30 days influence diagrams to Neu5Gc in rat body.
Specific embodiment
The present invention is described further below with reference to specific embodiment.
Embodiment 1: a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method, this method are as follows: treat government official's meat products
Living animal perfusion is administered by peroral routes of administration stomach-filling mode as Kaempferol, and Kaempferol amount is 200mg/ (kg.d), will
It uses 0.5% carboxymethylcellulose sodium solution to carry out being configured to 1mL solution, and each stomach-filling amount is 1mL/d, stomach-filling 30d, list
Position mg/ (kg.d) indicates that the living animal of every kg body weight wants the amount of stomach-filling is how many milligram daily.
Embodiment 2: a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method, this method are as follows: treat government official's meat products
Living animal perfusion is administered by peroral routes of administration stomach-filling mode as Kaempferol, and Kaempferol amount is 190mg/ (kg.d), will
It uses 0.5% carboxymethylcellulose sodium solution to carry out being configured to 1mL solution, and each stomach-filling amount is 1mL/d, stomach-filling 29d.
Embodiment 3: a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method, this method are as follows: treat government official's meat products
Living animal perfusion is administered by peroral routes of administration stomach-filling mode as Kaempferol, and Kaempferol amount is 210mg/ (kg.d), will
It uses 0.5% carboxymethylcellulose sodium solution to carry out being configured to 1mL solution, and each stomach-filling amount is 1mL/d, stomach-filling 31d.
Effect in order to further illustrate the present invention, is tested as follows:
Selection cleaning grade male SD rat 40, adaptive feeding observation 1 week, random four groups according to the original body mass of rat, often
Group 10.It is tested in a manner of peroral routes of administration stomach-filling, experimental group (is used with 200 mg/ of luteolin Kaempferol (kg.d)
0.5% carboxymethylcellulose sodium solution is prepared)；Blank control group is filled with 0.5% carboxymethylcellulose sodium solution
Stomach.Each stomach-filling amount is 1 mL/d.After 30 d of Kaempferol stomach-filling, 12 h of Rat Fast carries out ether daze vertebral fracture
It is lethal, solution is carried out to the rat after execution and takes thigh side muscles tissue, liver and kidney.Different disposal group is weighed later
The saturated ammonium sulfate of 10 mL 30% is added in 1 g meat sample and internal organ, and refiner is processed into meat and starches, and after vacuum freeze drying, is added
5 mL, 2 mol/L acetic acid, 80 DEG C of water-bath 3 h, 12000 r/15 min centrifugation removal solid contents, filter freezing dry and remove vinegar
Acid, gained drying sample are re-dissolved in 1 mL ultrapure water, and 0.2 mL, 0.1 mol/LNaOH is added and is taken off under the conditions of 37 DEG C
Acetyl handles 30 min, and 50 DEG C of water-bath 150min of DMB derivating agent are added in filtering, is cooled to room temperature and carries out HPLC detection.
What the synthesis of Neu5Gc played a crucial role is CMP-Neu5Ac hydroxylase, so the present invention uses natural flavonoids
Substance Kaempferol inhibits the substrate of CMP-Neu5Ac hydroxylase, and then influences the activity of CMP-Neu5Ac hydroxylase, reaches reduction
The synthesis of Neu5Gc carries out the intervention of NeuGc ALPHA2-3Gal biochemistry synthesis before killing in living body, at low cost, effect is brighter
It is aobvious.
As shown in Figure 1, alphabetical difference person represents and has differences significant (P < 0.05), the identical difference that represents of letter is not significant,
Similarly hereinafter.
Neu5Gc degradation rate calculates: Neu5Gc degradation rate/%=(C0- C1)/C0
In formula: C0Indicate the peak area of Neu5Gc in blank control, C1Indicate the peak area of Neu5Gc in experimental group sample.
Meat sample degradation rate: Kaempferol=13.356%
Liver sample degradation rate: Kaempferol=6.315%
Kidney sample degradation rate: Kaempferol=17.55%.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
Those familiar with the art in the technical scope disclosed by the present invention, can easily think of the change or the replacement, and should all contain
Within protection scope of the present invention, therefore, protection scope of the present invention should be based on the protection scope of the described claims lid.
Claims (2)
1. a kind of effectively inhibit NeuGc ALPHA2-3Gal synthetic method, it is characterised in that: this method are as follows: treat government official's meat products
Living animal fills Kaempferol, by peroral routes of administration stomach-filling mode, Kaempferol is molten using 0.5% sodium carboxymethylcellulose
Liquid carries out being configured to 1mL solution, and each stomach-filling amount is 1mL/d, stomach-filling 29-31d.
2. a kind of effectively inhibition NeuGc ALPHA2-3Gal synthetic method according to claim 1, it is characterised in that: mountain
How phenol amount is 190-210mg/ (kg.d).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811139284.7A CN109329202A (en) | 2018-09-28 | 2018-09-28 | It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811139284.7A CN109329202A (en) | 2018-09-28 | 2018-09-28 | It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109329202A true CN109329202A (en) | 2019-02-15 |
Family
ID=65307160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811139284.7A Pending CN109329202A (en) | 2018-09-28 | 2018-09-28 | It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109329202A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856578A (en) * | 2003-09-26 | 2006-11-01 | 雅玛山酱油株式会社 | Process for producing cmp-n-acetylneuraminic acid |
| CN102197131A (en) * | 2008-09-09 | 2011-09-21 | 加利福尼亚大学董事会 | Elimination of a contaminating non-human sialic acid by metabolic competition |
| CN107001449A (en) * | 2014-10-15 | 2017-08-01 | 芝诺锡拉公司 | The composition of immunogenicity with reduction |
-
2018
- 2018-09-28 CN CN201811139284.7A patent/CN109329202A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1856578A (en) * | 2003-09-26 | 2006-11-01 | 雅玛山酱油株式会社 | Process for producing cmp-n-acetylneuraminic acid |
| CN102197131A (en) * | 2008-09-09 | 2011-09-21 | 加利福尼亚大学董事会 | Elimination of a contaminating non-human sialic acid by metabolic competition |
| CN107001449A (en) * | 2014-10-15 | 2017-08-01 | 芝诺锡拉公司 | The composition of immunogenicity with reduction |
Non-Patent Citations (2)
| Title |
|---|
| KAZUYA L.P.J HIFARI等: "Identification and characterization of flavonoids as sialyltransferase inhibitors", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
| MURIEL BARDOR等: "Mechanism of Uptake and incorporation of the Non-human sialic Acid N-Glycolylneuraminic Acid into human cells", 《J BIOL CHEM.》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2265277T3 (en) | PREPARATION AND USE OF A SOLANUM GLAUCOPHYLUM PLANT EXTRACT WITH AN ENRICHED CONTENT OF 1,25-DIHYDROXY-D3-VITAMINE GLYCOSIDES AND QUERCETING LYCOSIDES | |
| Monsoro-Burq et al. | Heterogeneity in the development of the vertebra. | |
| CA2672155A1 (en) | Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases | |
| JP7457713B2 (en) | Composition for promoting cartilage regeneration | |
| CN109223763A (en) | It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method in meat products | |
| CN109329202A (en) | It is a kind of effectively to inhibit NeuGc ALPHA2-3Gal synthetic method | |
| JP2006225270A (en) | Tripeptide having sex hormone modification action, extract containing the same, eicosapentaenoic acid-bonded tripeptide, food preparation, cosmetic preparation and endometriosis treating agent containing the same | |
| WO2019172712A1 (en) | Functional food composition for enhancing muscular function and mobility and comprising lotus leaf extract, and method for preparing same | |
| CN102007110B (en) | For preventing, treat the Flavonol compound of bone health relevant disease, the bioactive extracts/fraction of elm and compound thereof | |
| CN109331007A (en) | A kind of inhibition NeuGc ALPHA2-3Gal synthetic method | |
| Connolly et al. | The effect of interscapular brown adipose tissue removal on body-weight and cold response in the mouse | |
| Balakrishnan et al. | Methanol extract of euchelus asper prevents bone resorption in ovariectomised mice model | |
| CN111875572A (en) | Prunus humilis procyanidin, preparation method, application and medicine thereof | |
| TWI382846B (en) | Pharmaceutical compositions and extracts for inhibiting formation and/or activation of osteoclasts and uses of the same | |
| CN101503721A (en) | Method for extracting swan-mussel polysaccharide | |
| WO2018226060A1 (en) | Composition for preventing or treating kidney disease including cudratricusxanthone a having kidney-protecting activity as active ingredient | |
| Zhang et al. | Dietary Selenomethionine Supplementation Limits Extracellular Trap Formation and Reduces Lesion Burden in a Mouse Model of Atherosclerosis | |
| Park et al. | Effect of hot-water extracts from Laminaria japonicus on melanin production in B16 melanoma cells | |
| CN106880627A (en) | Osthole as the ERs activator of α 36 purposes | |
| WO2023090542A1 (en) | Pharmaceutical composition containing hot water extract of fruit of vaccinium bracteatum thunb. as active ingredient for preventing or treating benign prostatic hyperplasia | |
| Supabphol et al. | Cytoprotective potential of royal jelly on human umbilical vein endothelial cells against nicotine toxicity via catalase. | |
| JP2011012022A (en) | Preventing or improving agent for hyperuricemia | |
| CN104530216A (en) | Method for extracting chorionic gonadotrophin from crude product by virtue of high-concentration salt solution extraction method | |
| KR20200145714A (en) | Composition for preventing or treating muscular diseases comprising glycyrrhiza uralensis fischer extract | |
| CN117599039A (en) | Use of flavonoid compounds and medicament for preventing and/or treating familial intestinal polyps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190215 |
|
| RJ01 | Rejection of invention patent application after publication |